Abstracts tagged "autoantibodies"

Abstract Number: 1692 • 2014 ACR/ARHP Annual Meeting
The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement
I.M. Markusse¹, J. Meijs², B. de Boer², A. a. Schouffoer¹, N. Ajmone Marsan³, L. J. M. Kroft⁴, M. K. Ninaber⁵, T. W. J. Huizinga² and J.K. de Vries-Bouwstra⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Cardiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Deparment of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Severe nailfold videocapillaroscopy (NVC) patterns in patients with systemic sclerosis (SSc) are associated with a high risk of organ involvement. SSc-specific autoantibodies seem to…
Abstract Number: 914 • 2014 ACR/ARHP Annual Meeting
A Predictive Model of Disease Outcome in Rituximab-Treated Myositis Patients Using Clinical Features, Autoantibodies, and Serum Biomarkers
Jeannette Olazagasti¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla¹, Rohit Aggarwal³, Chester V. Oddis⁴ and Ann M. Reed¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Develop predictive models of early (8 week) and late (24 week) disease outcomes using clinical features, autoantibodies, and serum biomarkers in patients with refractory…
Abstract Number: 2908 • 2014 ACR/ARHP Annual Meeting
Flip Deficiency in Dendritic Cells Promotes Spontaneous Arthritis Mediated By Reduced Treg and Increased Autoreactive CD4⁺t Cells
Qiquan Huang¹, Harris R. Perlman², Robert Birkett³, Renee E. Doyle⁴, Deyu Fang⁵, G Kenneth.Haines⁶, William H. Robinson⁷, Syamal K. Datta⁸, Hyewon Phee⁹ and Richard M. Pope¹⁰, ¹Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Mount Sinai Hospital School of Medicine, New York, New York, NY, ⁷VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁸Rheumatology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose Flip (CFLAR) has been identified as a rheumatoid arthritis (RA) risk allele and is important in preventing death receptor mediated apoptosis of dendritic cells…
Abstract Number: 1645 • 2014 ACR/ARHP Annual Meeting
Interferon Gene Signature Expression and Serological Differences in Japanese and Non-Japanese SLE Patients
Hitoshi Kohsaka¹, Kosuke Kotani², Tomonori Ishii³, Tomoya Miyamura⁴, Masato Okada⁵, Toshihiko Aranishi², R. Maciuca⁶, William P. Kennedy⁶ and Junko Ohata², ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences,, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Chugai Pharmaceutical co., ltd, Tokyo, Japan, ³Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁴Department of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan, ⁵Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁶Genentech, Inc, South San Francisco, CA
Background/Purpose: Elevated expression of interferon(IFN)-regulated genes in peripheral blood cells has been reported in systemic lupus erythematosus (SLE) patients and is known as the IFN…
Abstract Number: 887 • 2014 ACR/ARHP Annual Meeting
Serological and Clinical Characteristics of a Large Collection of Incomplete Lupus Erythematosus Patients
Teresa Aberle¹, Virginia C. Roberts¹, Julie M. Robertson¹, Joel M. Guthridge¹, Kathy L. Sivils², Astrid Rasmussen², David R. Karp³ and Judith James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁴Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Incomplete lupus (ILE) is defined as a condition in which patients present with signs of systemic autoimmunity and clinical manifestations compatible with systemic lupus…
Abstract Number: 2660 • 2013 ACR/ARHP Annual Meeting
Omega-3 Supplement Use Is Associated With a Reduced Risk Of Anti-Cyclic Citrullinated Protein Positivity In a Population Without Rheumatoid Arthritis, But At Risk For Future Disease
Ryan W. Gan¹, Kendra A. Young¹, Gary O. Zerbe², M. Kristen Demoruelle³, Michael H. Weisman⁴, Jane H. Buckner⁵, Peter K. Gregersen⁶, Ted R. Mikuls⁷, James R. O'Dell⁸, Richard M. Keating⁹, Michael J. Clare-Salzler¹⁰, Kevin D. Deane³, V. Michael Holers¹¹ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology Section, The University of Chicago, Chicago, IL, ¹⁰Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, ¹¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and circulating autoantibodies, which can be present in serum years prior to RA diagnosis and can…
Abstract Number: 1786 • 2013 ACR/ARHP Annual Meeting
91% Of Early RA Patients Are Positive For Serum 14-3-3η Or Its Auto-Antibodies
Walter P. Maksymowych¹, Dirkjan van Schaardenburg², Désirée van der Heijde³, Robert Landewé⁴, Gilles Boire⁵, Maarten Boers⁶, Vivian P. Bykerk⁷, Edward C. Keystone⁸, Katherine A. Siminovitch⁹, Mairead Murphy¹⁰ and Anthony Marotta¹¹, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Jan van Breemen Research Institute | Reade, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Int Med/Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁸Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Augurex Life Sciences Corp., North Vancouver, BC, Canada, ¹¹Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Current serological markers such as RF and ACPA are useful for early diagnosis and perhaps for screening people at risk, but there remains a…
Abstract Number: 873 • 2013 ACR/ARHP Annual Meeting
Health Fair Evaluations To Identify Subjects At-Risk For Future Inflammatory Arthritis and Rheumatoid Arthritis
Kristen E. Beck¹, M. Kristen Demoruelle², Christopher C. Striebich³, Kaylynn Aiona⁴, Marie L. Feser², Lezlie A. Derber⁵, Stacey Brake⁶, Jill Lysengen⁷, Laura Rosseisen⁷, Julia J. Rhiannon⁸, Stuart M. Weisman⁵, Jill M. Norris⁹, V. Michael Holers¹⁰ and Kevin D. Deane², ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³University of Colorado Denver, Aurora, CO, ⁴Colorado School of Public Health, Aurora, CO, ⁵University of Colorado School of Medicine, Division of Rheumatology, Aurora, CO, ⁶9Health Fair, Denver, CO, ⁷Arthritis Foundation, Great West Region, Denver Office, Denver, CO, ⁸Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁹Epidemiology, Colorado School of Public Health, Aurora, CO, ¹⁰Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Multiple studies demonstrate that there is a preclinical period of rheumatoid arthritis (RA) when autoantibodies (Abs) including RF and anti-CCP are abnormal in absence…
Abstract Number: 2645 • 2013 ACR/ARHP Annual Meeting
Pathological Roles Of The Anti-Oxidative Enzyme Peroxiredoxin 2 In Patients With Kawasaki Disease
Rie Karasawa¹, Toshiko Sato¹, Mayumi Tamaki¹, Mikiya Fujieda², Kazuhide Ohta³ and Kazuo Yudoh¹, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Pediatrics, Kochi Medical School, Nankoku, Japan, ³Department of Pediatrics, Kanazawa Medical Center, Kanazawa, Japan
Background/Purpose: Anti-endothelial cell antibodies (AECA) are autoantibodies that are detected frequently in vasculitis caused by, for example, Kawasaki disease (KD). However, AECA target molecules have…
Abstract Number: 1635 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Genetic Associations Within Major Histocompatibility Complex (MHC) Class I and Class II In Systemic Lupus Erythematosus (SLE) Patients: An Examination Of Epitopes Of Early Autoimmunity
Gerard Dumancas¹, Chee Paul Lin², Indra Adrianto¹, Jennifer A. Kelly¹, Stuart B. Glenn¹, Jourdan Anderson², John B. Harley^3,4, Timothy J. Vyse⁵, Robert P. Kimberly⁶, Marta E. Alarcon-Riquelme⁷, Carl D. Langefeld⁸, Betty P. Tsao⁹, Lindsey A. Criswell¹⁰, Chaim O. Jacob¹¹, Patrick M. Gaffney¹², Kathy Sivils¹², Judith A. James^12,13 and Courtney Montgomery², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁵Medical & Molecular Genetics, King's College London, London, United Kingdom, ⁶Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁸Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ¹⁰Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production, multiple organ involvement, strong genetic predisposition and specifically, to be associated with…
Abstract Number: 809 • 2013 ACR/ARHP Annual Meeting
IgM Rheumatoid Factor As a Potentiator Of Anti-Citrullinated Protein Antibody Mediated Inflammation In Rheumatoid Arthritis
Jeremy Sokolove¹, Danye Cheng², Dannette S. Johnson³, Ted R. Mikuls⁴ and William H. Robinson⁵, ¹VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ²VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ³Rheumatology, Jackson VA and University of Mississippi Medical Center, Jackson, MS, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: The co-occurrence of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) is well described in rheumatoid arthritis (RA), and has been associated with…
Abstract Number: 2575 • 2013 ACR/ARHP Annual Meeting
Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory
Masataka Kuwana¹, Yuichiro Shirai¹, Hidekata Yasuoka¹, Tsutomu Takeuchi¹ and Kenichi Masui², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is an intractable complication of connective tissue disease (CTD). Current guidelines recommend early detection and intervention for improvement of outcomes.…
Abstract Number: 1612 • 2013 ACR/ARHP Annual Meeting
Rituximab For Treatment Of Refractory Auto-Immune Hepatitis
Chadi Rakieh¹, Edward M. Vital², Paul Emery³ and Michael Martin¹, ¹Rheumatology, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom, ²Section of Musculoskeletal Disease, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom, ³Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom
Background/Purpose: Auto-immune hepatitis (AIH), also known as lupoid hepatitis, is a chronic progressive disease of unknown aetiology. First-line therapy consists of corticosteroids alone or in…
Abstract Number: 810 • 2013 ACR/ARHP Annual Meeting
Inducible Bronchus Associated Lymphoid Tissue In The Lung Is Associated With Seropositivity For Rheumatoid Arthritis-Related Autoantibodies In Subjects With and Without Clinically Diagnosed Rheumatoid Arthritis
M. Kristen Demoruelle¹, Adam W. Bagley², Mark C. Parish¹, David E. Heinz³, V. Michael Holers⁴, Carlyne D. Cool⁵ and Kevin D. Deane¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ³Pathology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁵University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Data suggest the lung may be a site of RA-related autoantibody (Ab) generation including findings of airways inflammation prior to onset of articular RA…
Abstract Number: 2539 • 2013 ACR/ARHP Annual Meeting
The Reliability Of a Novel Automated System For ANA Immunofluorescence Analysis In Daily Clinical Practice
Mohammed Alsuwaidi¹, Margit Dollinger¹, Martin Fleck^1,2 and Boris P. Ehrenstein¹, ¹Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, ²Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany
Background/Purpose: Recently, automated interpretation (AI) systems for anti-nuclear antibody (ANA) analysis have been introduced based on assessment of indirect immunofluorescence (IIF) patterns. However, the reliability…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.